Skip to main content

Advertisement

Table 3 Baseline characteristics and outcomes of the patients

From: Neuromuscular blocking agents in patients with acute respiratory distress syndrome: a summary of the current evidence from three randomized controlled trials

  Cisatracurium Control p value SMD / RR Heterogeneity p value
(n= 223) (n= 208)   (95% Confidence Interval)   
Age, years 56.60 ± 4.08 60.16 ± 1.89 0.300**    
Lung injury score 2.94 ± 0.07 2.86 ± 0.09 0.667**    
SAPS II 46.26 ± 4.14 47.13 ± 1.80 0.999**    
Onset of ARDS, days 0.90 ± 0.13 0.98 ± 0.31 0.700**    
Days receiving mechanical ventilation 1.80 ± 1.26 2.13 ± 1.78 0.667**    
Change in PaO2 / FiO2 * 93.66 ± 40.12 42.66 ± 4.04 0.050** SMD: 0.29 (0.09 – 0.49) 0.320 0.004
Change in PaCO2 *, mmHg 8.76 ± 27.1 10.66 ± 23.80 0.150** SMD: 0.02 (-0.17 – 0.21) 0.520 0.800
Change in PEEP*, cmH2O - 2.20 ± 1.90 - 0.46 ± 0.56 0.050** SMD: -0.18 (-0.37 – 0.01) 0.430 0.060
Change in VT *, mL/kg 0.28 ± 0.33 0.30 ± 0.11 0.150** SMD: -0.02 (-0.21 – 0.17) 0.300 0.850
Change in FiO2 *, % - 25.40 ± 7.91 - 13.10 ± 7.39 0.050** SMD: -0.31 (-0.50 – -0.12) 0.260 0.002
Change in Plateau Pressure*, cmH2O - 3.66 ± 1.49 - 0.70 ± 0.60 0.050** SMD: -0.11 (-0.30 – 0.08) 0.040 0.250
Ventilator-free days at day 28, days 6.76 ± 3.51 5.20 ± 3.40   SMD: 0.22 (0.03 – 0.41) 0.860 0.020
Barotrauma, n (%) 9 (4.0) 20 (9.6)   RR: 0.45 (0.22 – 0.92) 0.830 0.030
Critical illness neuromyopathy, n (%) 41 (18.3) 29 (13.9)   RR: 1.13 (0.76 – 1.66) 0.990 0.550
ICU mortality, n (%) 70 (31.4) 93 (44.7)   RR: 0.71 (0.55 – 0.90) 0.620 0.005
Mortality at day 28 after inclusion, n (%) 52 (23.3) 71 (34.1)   RR: 0.68 (0.51 – 0.92) 0.580 0.010
  1. SAPS: Simplified acute physiology score; ARDS: Acute respiratory distress syndrome; PEEP: Positive end expiratory pressure; VT: Tidal volume; FiO2: Fraction of inspired oxygen; ICU: Intensive care unit.
  2. * Change in these variables were calculated as follow: (last value of the follow-up) – (baseline value).
  3. ** Mann-Whitney Exact Test.
  4. SMD calculated with the values in the final period of follow-up.